Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke

Sverre E. Kjeldsen, Paulette A. Lyle, Jorge R. Kizer, Suzanne Oparil, Aud Høieggen, Ingrid Os

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

A fixed-dose combination of losartan/hydrochlorothiazide (HCTZ) therapy may be a logical choice for antihypertensive treatment, including for initial therapy in patients with blood pressure elevation >20/10 mmHg above treatment target. The renin-angiotensin-aldosterone-system-activating effect of hydrochlorothiazide augments the efficacy of blocking the angiotensin II type 1 (AT) receptor with losartan. Some adverse effects associated with hydrochlorothiazide, including increased risk for new-onset diabetes mellitus, may be offset by losartan. Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group. The efficacy, tolerability, and convenience of losartan/HCTZ combination therapy may increase patient compliance and lower risk for stroke, a devastating outcome in patients with hypertension.

Original languageEnglish (US)
Pages (from-to)299-305
Number of pages7
JournalVascular Health and Risk Management
Volume3
Issue number3
StatePublished - Aug 14 2007

    Fingerprint

Keywords

  • Angiotensin receptor blocker
  • Combination therapy
  • Hydrochlorothiazide
  • Hypertension
  • Stroke

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Kjeldsen, S. E., Lyle, P. A., Kizer, J. R., Oparil, S., Høieggen, A., & Os, I. (2007). Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. Vascular Health and Risk Management, 3(3), 299-305.